P21 for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

P21 for Health & Longevity

Created on 10/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

P21 is a small laboratory-made peptide derived from a natural nerve-growth protein, of interest for protecting memory and brain function with age. Rodent studies, nearly all from the developer's laboratory, reported better memory, more new brain cells and less Alzheimer-type protein build-up; it is untested in people, and no pharmaceutical-grade product is available. Risks include possible appetite and weight loss, impure online products and theoretical tumor and pregnancy concerns. (Full Review)

Protocol

Community intranasal regimen
500–1000 µg once daily
For 8–12 weeks, as listed by the Peptide Initiative; no human-equivalent dose has been validated
Community subcutaneous regimen
375 µg/day
8-week protocol, as listed by the vendor-affiliated Biomogging guide
Route
Intranasal or subcutaneous injection
Mostly chosen by community users; oral use worked in rodents, but human oral bioavailability is unknown; community protocols use one daily dose; time of day: no data exist, morning dosing is common practice
Time to effect
P21 in rodent studies
6–12 months
Effects measured after 6–12 months of P21; human onset is unknown
Parent Peptide 6 in rodents
30 days
Effects measured after 30 days of the parent Peptide 6, a different compound; human onset is unknown

Benefits

Contraindications
  • Women who are pregnant, breastfeeding or trying to conceive
  • People with active cancer or receiving cancer treatment
  • Children and adolescents
  • People with a history of allergic reaction to peptide products
  • People who are underweight or have an eating disorder
    •
Key Interactions
  • Pan-Trk cancer drugs, which block all Trk growth receptors (larotrectinib, entrectinib): Avoid (theoretical)
  • Fertility medications (clomiphene citrate, letrozole, follitropin alfa): Avoid (theoretical)
  • GSK-3 inhibitors (lithium carbonate): Caution (theoretical)
  • Lithium orotate supplements: Caution (theoretical)
  • Antidepressants that raise BDNF (sertraline, escitalopram): Monitor (theoretical)
  • TrkB-activating supplements (7,8-dihydroxyflavone): Caution (theoretical)
  • Other nootropic (memory-enhancing) peptides (Semax, Cerebrolysin, Dihexa): Caution (theoretical)
  • Over-the-counter nasal decongestants (oxymetazoline, phenylephrine sprays): Caution (theoretical)
    •

Risk & Side Effects

  • Low: Appetite Loss and Weight Loss
    •
  • Speculative: Contaminated or Mislabeled Product; Growth Signaling and Tumor Promotion; Impaired Embryo Implantation; Immune Reaction to the Peptide; Headache, Nasal Irritation and Mood Changes
    •

Monitoring

Marker Target Why
ALT (liver enzyme) 7–55 U/L Safety check: a rise stops use
AST (liver and muscle enzyme) 8–48 U/L Safety check: a rise stops use
Creatinine (kidney filtration) 0.59–1.35 mg/dL Safety check: a rise stops use
White blood cell count 3.4–9.6 × 10⁹/L Safety check: a rise with fever stops use
Serum hCG (pregnancy hormone) Negative, below 5 IU/L Safety check: a positive result stops use
Body weight No unintended loss over 5% of starting weight Safety check: the parent protein caused appetite loss
Serum BDNF (brain growth factor) No established target; track change from own baseline Expected to change: P21 raises this brain growth factor in animals
Plasma p-tau217 (blood form of tau, an Alzheimer-linked protein) No established target; track change from own baseline Expected to change: P21 lowered tau in animals
Validated cognitive test (e.g., Montreal Cognitive Assessment) Improvement over own baseline on the same test Defines success; no target result has been validated for P21

Cadence: Weight weekly; repeat blood tests at 4 weeks, at the end of each 8–12-week cycle, then every 6 months while use continues; cognitive testing at the end of each cycle.

Qualitative Assessment

  • Memory for names, appointments and new information
  • Word-finding and mental clarity
  • Sleep quality and dream changes
  • Mood stability
  • Appetite and unintended weight change
  • Nasal irritation or injection-site reactions
  • Headaches
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.